Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis.
João Pedro Machado Ribeiro Jacintho Silva, Bruno Viruez Nogueira, Deborah Lomelino Sartori et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated cardiovascular outcomes of tirzepatide versus GLP-1 receptor agonists in adults with overweight or obesity, analyzing data from eight studies involving 323,439 patients. The findings indicated that tirzepatide was not associated with a statistically significant reduction in major adverse cardiovascular events (MACE) compared to GLP-1 receptor agonists (HR 0.85, 95% CI 0.70-1.04).
Key findings
- Tirzepatide did not significantly reduce major adverse cardiovascular events compared to GLP-1 receptor agonists (HR 0.85).
- Substantial heterogeneity was observed across the studies included in the analysis.
- In patients with type 2 diabetes, lower risks of all-cause mortality were estimated (HR 0.85).
- Exploratory analyses suggested lower heart failure risks in the same subgroup (HR 0.75).
Why it matters
Understanding the cardiovascular outcomes associated with different obesity treatments is crucial for clinicians to make informed decisions about patient management and to weigh the benefits and risks of therapies like tirzepatide versus traditional GLP-1 receptor agonists.
What to keep in mind
The study included a predominance of observational studies and exhibited substantial heterogeneity, which limits causal interpretation of the results.